Rasdegafusp alfa - Celldex Therapeutics

Drug Profile

Rasdegafusp alfa - Celldex Therapeutics

Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex; Rasdegafusp alfa

Latest Information Update: 01 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Fallopian tube cancer; Gynaecological cancer; Malignant melanoma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 May 2018 Discontinued - Phase-I for Chronic myelomonocytic leukaemia (Combination therapy) in USA (SC)
  • 17 May 2018 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top